Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More
Employees: 11-50
Total raised: $42.41M
Founded date: 2019
Investors 5
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| 08.11.2022 | British Pa... | britishpat... |
| - | Oxford Uni... | innovation... |
| - | Creative D... | creativede... |
| - | Oxford Sci... | oxfordscie... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.10.2022 | Series A | $42.41M | British Pa... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 21.10.2022 | British Patient Capital invests £7.5 million in biotechnolog... | 19 October 2022 British Patient Capital has invested £7.5 million in Nucleome Therapeutics, a biote... | britishpat... |
| 20.10.2022 | Startup using machine learning to find new medicines raises ... | Biotech startup Nucleome Therapeutics has raised £37.5m in an oversubscribed Series A round to disco... | uktech.new... |
| 19.10.2022 | Nucleome Therapeutics Raises £37.5M in Series A Financing | Nucleome Therapeutics, an Oxford, UK-based biotechnology company decoding the dark matter of the hum... | finsmes.co... |
| 19.10.2022 | Nucleome Therapeutics raises oversubscribed £37.5 million Se... | Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matt... | globenewsw... |
| - | Nucleome Therapeutics | - | fastfounde... |